News about "chronic obstructive pulmonary disease (COPD) "

China Approves Trelegy Ellipta for Uncontrolled Asthma

China Approves Trelegy Ellipta for Uncontrolled Asthma

China has approved Trelegy Ellipta for adults with uncontrolled asthma, extending its use beyond COPD and making it the only single-inhaler triple therapy for both conditions in the country.

Chronic Obstructive Pulmonary Disease (COPD) | 27/01/2026 | By News Bureau 192

Generate:Biomedicines to Begin Phase 3 Trials of AI-Engineered Asthma Antibody GB-0895

Generate:Biomedicines to Begin Phase 3 Trials of AI-Engineered Asthma Antibody GB-0895

Generate:Biomedicines is set to begin its first global Phase 3 trials for GB-0895, an AI-engineered long-acting anti-TSLP antibody for patients with severe, uncontrolled asthma. The SOLAIRIA-1 and SOLAIRIA-2 studies will evaluate the therapy in about 1,600 patients, marking a key milestone for programmable biology in respiratory care.

Chronic Obstructive Pulmonary Disease (COPD) | 02/12/2025 | By Dineshwori 298

GSK and Empirico Sign Licensing Deal for Respiratory Oligonucleotide

GSK and Empirico Sign Licensing Deal for Respiratory Oligonucleotide

Oligonucleotide therapies, including siRNA, offer the potential to modulate gene expression and target diseases beyond the reach of traditional drugs. EMP-012 adds to GSK’s growing oligonucleotide pipeline across respiratory, immunology and inflammation, and infectious disease portfolios.

Chronic Obstructive Pulmonary Disease (COPD) | 29/10/2025 | By Dineshwori 267

Fosun Pharma and Expedition Therapeutics Enter Global Licensing Agreement for Innovative Respiratory Drug XH-S004

Fosun Pharma and Expedition Therapeutics Enter Global Licensing Agreement for Innovative Respiratory Drug XH-S004

Fosun Pharma Industrial has signed a global License Agreement with Expedition Therapeutics Inc., granting the US-based biotechnology company the rights to develop, manufacture, and commercialise its investigational respiratory drug XH-S004 in all regions worldwide, excluding the Chinese Mainland, Hong Kong SAR, and Macau SAR.

Chronic Obstructive Pulmonary Disease (COPD) | 13/08/2025 | By Dineshwori 291

Merck to Acquire Verona Pharma for USD 10 Billion to Expand Cardio-Pulmonary Portfolio

Merck to Acquire Verona Pharma for USD 10 Billion to Expand Cardio-Pulmonary Portfolio

Merck, through a subsidiary, will acquire Verona Pharma for USD 107 per American Depository Share (ADS), each of which represents eight shares of Verona Pharma, for a total transaction value of approximately USD 10 billion.

Chronic Obstructive Pulmonary Disease (COPD) | 10/07/2025 | By Dineshwori 457


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members